Dimensional Fund Advisors LP Purchases 63,370 Shares of Bio-Rad Laboratories, Inc. $BIO

Dimensional Fund Advisors LP increased its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 6.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,062,938 shares of the medical research company’s stock after buying an additional 63,370 shares during the period. Dimensional Fund Advisors LP owned 3.93% of Bio-Rad Laboratories worth $298,019,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. First Eagle Investment Management LLC boosted its stake in Bio-Rad Laboratories by 60.7% during the 2nd quarter. First Eagle Investment Management LLC now owns 2,517,313 shares of the medical research company’s stock valued at $607,478,000 after purchasing an additional 951,123 shares during the period. Ariel Investments LLC boosted its position in shares of Bio-Rad Laboratories by 13.0% in the second quarter. Ariel Investments LLC now owns 818,624 shares of the medical research company’s stock valued at $197,550,000 after acquiring an additional 93,964 shares during the period. Bank of America Corp DE grew its stake in shares of Bio-Rad Laboratories by 5.0% in the second quarter. Bank of America Corp DE now owns 452,133 shares of the medical research company’s stock worth $109,109,000 after acquiring an additional 21,594 shares during the last quarter. Westfield Capital Management Co. LP increased its position in Bio-Rad Laboratories by 11.5% during the third quarter. Westfield Capital Management Co. LP now owns 155,524 shares of the medical research company’s stock worth $43,607,000 after acquiring an additional 16,019 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its stake in Bio-Rad Laboratories by 3.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 134,767 shares of the medical research company’s stock valued at $40,154,000 after purchasing an additional 4,262 shares during the last quarter. Institutional investors own 65.24% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on BIO. Weiss Ratings restated a “sell (d-)” rating on shares of Bio-Rad Laboratories in a report on Monday, December 29th. Wall Street Zen downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $358.50.

Bio-Rad Laboratories Trading Down 3.2%

Shares of Bio-Rad Laboratories stock opened at $270.00 on Friday. Bio-Rad Laboratories, Inc. has a 12-month low of $211.43 and a 12-month high of $343.12. The stock has a market capitalization of $7.29 billion, a P/E ratio of 9.67 and a beta of 1.18. The company has a 50-day simple moving average of $295.78 and a 200 day simple moving average of $301.09. The company has a quick ratio of 4.19, a current ratio of 5.62 and a debt-to-equity ratio of 0.16.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings results on Thursday, February 12th. The medical research company reported $2.51 EPS for the quarter, missing analysts’ consensus estimates of $2.57 by ($0.06). The firm had revenue of $693.20 million during the quarter, compared to analyst estimates of $694.64 million. Bio-Rad Laboratories had a net margin of 29.42% and a return on equity of 3.86%. Bio-Rad Laboratories’s quarterly revenue was up 3.9% on a year-over-year basis. During the same quarter last year, the firm earned $2.90 earnings per share. Research analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.